FAIM
TARA icon

Financial Advocates Investment Management’s Protara Therapeutics TARA Stock Holding History

Financial Advocates Investment Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,187
Closed -$678K – 864
2022
Q3 		$678K Buy
+6,187
New +$21K 0.06% 336
2022
Q1 		– Sell
-5,568
Closed -$598K – 812
2021
Q4 		$598K Buy
+5,568
New +$38.4K 0.04% 439

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PFMU
Privium Fund Management (UK) London, United Kingdom $240M AUM 10.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Financial Advocates Investment Management's TARA Position: Q4 2022 in Review

Financial Advocates Investment Management sold out of Protara Therapeutics (TARA) in Q4 2022, closing a stake of 6,187 shares — an estimated $678K sold.

Financial Advocates Investment Management first reported a position in TARA in Q4 2021 and held it in 2 quarters. The position peaked at $678K in Q3 2022. 31 funds tracked by Wall St. Rank hold TARA as of Q4 2022.

  • Financial Advocates Investment Management reported no remaining Protara Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 6,187 Protara Therapeutics shares in Q4 2022, an estimated $678K.
  • Financial Advocates Investment Management first reported a position in Protara Therapeutics in Q4 2021 and held it in 2 quarters.
  • Financial Advocates Investment Management's Protara Therapeutics position peaked at $678K in Q3 2022.
  • 31 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2022.

Based on Financial Advocates Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.